22ND Century Group Inc

This proposal asks stockholders to authorize the Board to amend the Articles of Incorporation to effect a reverse stock split at any ratio between 1‑for‑2 and 1‑for‑200, with the Board retaining sole discretion to select the ratio, the timing within the authorized period, or to abandon the split altogether. Management is pursuing this authorization primarily to address noncompliance or potential noncompliance with Nasdaq’s $1.00 minimum bid price rule and thereby avoid delisting from Nasdaq. The proposal expressly does not reduce the number of authorized shares, which would create a larger pool of unissued shares post‑split that the Board could use without further shareholder approval, raising potential dilution and anti‑takeover considerations. The company discloses a history of multiple recent reverse splits, indicating recurring listing‑price pressure and a pattern that investors should weigh when assessing marginal benefits of additional splits. The Board’s discretionary authority to choose any ratio within a very wide range (1:2 to 1:200) gives it flexibility to react to market conditions but reduces predictability for shareholders about share count and fractional‑share treatment. Management also highlights tax and accounting neutrality for the company and that proportional adjustments will be made to outstanding convertible instruments, though outstanding plan reserve counts will effectively increase post‑split. The stated benefits include potentially improved market perception and institutional interest if the share price increases, while management admits there is no assurance the split will produce sustained price improvement and emphasizes risks to liquidity and relative market capitalization. Given the retained ability to issue additional shares without reducing authorized shares, the transaction should be evaluated both for its immediate listing‑related utility and for the governance and dilution implications posed by a larger unissued share pool after the split.

Proposal 2 asks shareholders to ratify the issuance of inducement warrants granted in June 2026 and to approve the shares issuable upon exercise under Nasdaq Rule 5635(d) because the potential aggregate issuance could exceed Nasdaq’s 19.99% threshold at a price below the Minimum Price. The inducement transaction re‑prices or replaces existing warrants to incentivize original warrant holders to exercise and provide capital; the warrants are exercisable only after shareholder approval and have expirations five years after issuance. Management describes mechanics including anti‑dilution resets on exercise price upon future low‑priced equity issuances and an existing adjustment following a June 12, 2026 reverse split that set the current exercise terms at 3,019,586 warrants exercisable at $6.32. The company warns that failure to approve would render the inducement warrants non‑exercisable, requiring repeated shareholder meetings every 90 days until approval is obtained, and could deter future investors and complicate capital raising. Approving the proposal will be dilutive to current holders; management frames the tradeoff as necessary to preserve financing flexibility and to allow the company to avoid immediate adverse outcomes such as inability to monetize existing warrant exercises. From a governance perspective, shareholders should weigh the short‑term financing benefits against the dilution risk and the economic terms of the adjusted exercise price and anti‑dilution provisions. The Board’s recommendation is driven by pragmatic financing considerations and Nasdaq compliance, rather than by a strategic long‑term capital‑structure re‑design.

Proposal 3 requests approval for a contemplated private financing consisting of up to $20 million of a new convertible preferred with attached warrants, designed to be substantially similar to the Series B Preferred issued in March 2026, and to be completed within three months of the Special Meeting. Management intends the securities to be convertible into common stock at a conversion price tied to the Nasdaq Minimum Price (with a regulatory floor of 20% of that price), including customary anti‑dilution adjustments and beneficial‑ownership caps (4.99% default, 9.99% upon election) and optional cashless exercise mechanics for warrants if resales are not registered. The structure gives purchasers conversion protections (optional holder conversion, mandatory company conversion under certain market thresholds) and bespoke governance protections (preemptive rights, restrictions on altering rights without preferred‑holder consent), which are attractive to investors but may constrain corporate flexibility while preferred shares remain outstanding. Management frames approval as required by Nasdaq Rule 5635(d), because the potential issuance could exceed Nasdaq’s 19.99% threshold at prices below the Minimum Price, thereby necessitating shareholder consent for Nasdaq compliance. If not approved, management warns that future investors may be discouraged, potentially impairing the company’s ability to raise capital on favorable terms; if approved, the offering would be dilutive and could materially change capital structure and ownership dynamics. The proposal should be evaluated in light of the company’s capital needs, the dilution and control implications of convertible preferred with broad anti‑dilution and conversion features, and the identity and terms of likely purchasers (notably, the proposal contemplates substantially the same investor base as the March 2026 Series B purchasers). From a governance and financial strategy perspective, the offering trades immediate liquidity and investor commitments for longer‑term dilution and potential conversion that could significantly increase common share count if converted or exercised.

Proposal 4 seeks stockholder authorization for a contemplated financing of up to $10 million of common stock (or pre‑funded warrants in lieu of shares) accompanied by one warrant per share purchased, exercisable into additional common stock, with aggregate closings to be completed within three months using substantially the same investors as the warrant inducement. The offering includes contractual restrictions typical for private purchases (lock‑ups on new issuances for defined periods, investor participation rights in future offerings, and limitations on variable‑rate transactions), and the warrants will be exercisable for five years with anti‑dilution and beneficial‑ownership protections similar to the preferred‑related warrants. Management frames this request as necessary under Nasdaq Rule 5635(d) because the potential issuance could exceed 19.99% at prices below the Nasdaq Minimum Price and thus requires stockholder approval. If not approved, management warns that investor appetite may be dampened and capital raising could become more difficult; if approved, current shareholders will face dilution. The financing structure—including cashless exercise provisions, beneficial‑ownership caps, and sale restrictions—balances investor protections and company needs, but shareholders should scrutinize exercise pricing mechanics, the identity of purchasers, and the cumulative dilution if both this offering and the preferred offering in Proposal 3 proceed. From a corporate finance standpoint, the proposal trades immediate liquidity against long‑term dilution and potential shifts in shareholder base and control if warrants are exercised en masse.

Proposal 5 asks shareholders to permit the Board and management to adjourn the Special Meeting to a later date or time if votes in favor of Proposals 1–4 are insufficient at the scheduled meeting, enabling additional proxy solicitation and outreach to change or obtain votes. Management presents this as a procedural authorization to ensure that the company can secure the approvals necessary to implement the Reverse Split and complete the financings described in Proposals 2–4 without having to call new meetings repeatedly. The adjournment power is typical in contested or close vote contexts and reduces transaction execution risk by allowing more time for investor engagement, but it also permits management to continue soliciting proxies which could raise concerns about timing and fairness among holders who vote early. If approved, adjournment may lead to further disclosure and solicitation expenses and delay finality, but it increases the probability that the company can obtain the quorum and affirmative votes needed for Nasdaq compliance and financing objectives. Opponents could view the adjournment authorization as a mechanism to exert additional persuasion on undecided shareholders, though management states the purpose is strictly to obtain sufficient affirmative votes for critical Nasdaq‑related items. The decision to grant adjournment authority should be viewed in the context of the narrow time windows for the Proposed Offerings and Nasdaq compliance pressures described elsewhere in the proxy.